title: Dopaminergic innervation of the human striatum in Parkinson's disease.
abstract: In Parkinson's disease (PD), dopaminergic input to the caudate nucleus and a band of putaminal tissue abutting the external globus pallidus seems well preserved on immunohistochemical staining for the dopamine transporter. Counting of dopaminergic terminals showed that terminal density in these regions in PD was the same as that in controls, which indicates that input is truly preserved and not a consequence of a compensatory upregulation of metabolism in a reduced pool of surviving terminals. When the branching pattern of dopaminergic axons coursing through the globus pallidus was examined, we found no evidence for increased axonal sprouting in PD that might have contributed to preservation of dopaminergic input to the putamen or caudate nucleus. Although terminal counting indicated that anatomic input was preserved to parts of the striatum, dopamine uptake site density in these regions was reduced significantly. This suggests that the impact of disease in these areas is more profound than was thought previously.
authors.affiliation: Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
authors.forename: Michelle
authors.initials: M
authors.lastname: Porritt
authors.forename: Davor
authors.initials: D
authors.lastname: Stanic
authors.forename: David
authors.initials: D
authors.lastname: Finkelstein
authors.forename: Peter
authors.initials: P
authors.lastname: Batchelor
authors.forename: Sharon
authors.initials: S
authors.lastname: Lockhart
authors.forename: Andrew
authors.initials: A
authors.lastname: Hughes
authors.forename: Renate
authors.initials: R
authors.lastname: Kalnins
authors.forename: David
authors.initials: D
authors.lastname: Howells
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008297:Male; D008454:Mazindol / Q000493:pharmacokinetics*; D008562:Membrane Glycoproteins / Q000378:metabolism; D026901:Membrane Transport Proteins / Q000378:metabolism; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism*; D011180:Postmortem Changes; D011485:Protein Binding / Q000187:drug effects / Q000502:physiology; D014316:Tritium / Q000493:pharmacokinetics
chemical_list: D050483:Dopamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D014316:Tritium; D008454:Mazindol; D004298:Dopamine